MARKET

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6208
-0.0092
-1.46%
After Hours: 0.6300 +0.0092 +1.48% 19:53 05/24 EDT
OPEN
0.6100
PREV CLOSE
0.6300
HIGH
0.6300
LOW
0.5810
VOLUME
1.23M
TURNOVER
0
52 WEEK HIGH
3.590
52 WEEK LOW
0.4803
MARKET CAP
65.86M
P/E (TTM)
-1.0319
1D
5D
1M
3M
1Y
5Y
Cybin, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 15.60% at $0.68
Benzinga · 1d ago
Psychedelic Stock Gainers And Losers From May 20, 2022
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 8.33% at $0.77
Benzinga · 4d ago
Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 21.90% at $0.29
Benzinga · 5d ago
The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 6d ago
Seelos Therapeutics to get US patent for SLS-007 linked to treating neurodegenerative diseases
Seelos Therapeutics (NASDAQ:SEEL) said it received a notice of allowance for a U.S. patent for SLS-007, related to methods to treat neurodegenerative diseases. The U.S. patent application 16/833,515 from the U.S. Patent and
Seekingalpha · 6d ago
BRIEF-Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007
reuters.com · 6d ago
Seelos Therapeutics Receives A Notice Of Allowance In The US For An Additional Patent For SLS-007
NEW YORK, May 18, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare
Benzinga · 6d ago
Seelos Therapeutics Gets Notice of Allowance for US Patent for Neurodegenerative Disease Drug SLS-007
MT Newswires · 6d ago
More
No Data
Learn about the latest financial forecast of SEEL. Analyze the recent business situations of Seelos Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SEEL stock price target is 6.17 with a high estimate of 12.00 and a low estimate of 3.000.
High12.00
Average6.17
Low3.000
Current 0.6208
EPS
Actual
Estimate
-0.22-0.17-0.11-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 115
Institutional Holdings: 40.98M
% Owned: 38.63%
Shares Outstanding: 106.09M
TypeInstitutionsShares
Increased
36
2.34M
New
13
2.00M
Decreased
23
2.17M
Sold Out
23
1.63M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.78%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/President/Chief Executive Officer/Director
Raj Mehra
Chief Financial Officer
Michael Golembiewski
Director
Daniel O'Connor
Independent Director
Margaret Dalesandro
Independent Director
Brian Lian
Independent Director
Richard Pascoe
No Data
No Data
About SEEL
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company’s lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. It is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The Company’s ongoing programs include SLS-004, SLS-006, SLS-007, and SLS-008.

Webull offers kinds of Seelos Therapeutics Inc stock information, including NASDAQ:SEEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SEEL stock methods without spending real money on the virtual paper trading platform.